Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
Recruiting in Palo Alto (17 mi)
+27 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Surface Pharmaceuticals, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop. The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.
Research Team
KH
Kamran Hosseini, MD, PhD
Principal Investigator
Surface Ophthalmics, Inc. (formerly Surface Pharmaceuticals, Inc.)
Eligibility Criteria
Inclusion Criteria
Conjunctival hyperemia score of greater than or equal to 2 in the study eye when using the conjunctival hyperemia reference photos
Schirmer's Tear Test score (with anesthesia) greater than 1 mm but less than or equal to12 mm in the study eye
Female subjects of childbearing potential must agree to and submit a negative urine pregnancy test before any study-specific procedures are performed. The subjects must be using and continue to use a suitable method of contraception for the duration of the study: spermicide with barrier, oral contraceptive, transdermal contraceptive, injectable or implantable contraceptive, intrauterine device (IUD), abstinence or surgical sterilization of a partner. If a subject is not of childbearing potential (e.g., has been postmenopausal for at least 12 months or is premenarchal, or has undergone a hysterectomy, bilateral oophorectomy or a bilateral tubal ligation), a urine pregnancy test and use of a suitable method of contraception for the duration of the study will not be required.
See 7 more
Treatment Details
Interventions
- 0.02% Betamethasone Sodium Phosphate (Corticosteroid)
- 0.04% Betamethasone Sodium Phosphate (Corticosteroid)
- Placebo (Drug)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: SURF-200 (0.04% betamethasone sodium phosphate in vehicle)Experimental Treatment1 Intervention
One drop BID in the study eye for 14 days.
Group II: SURF-200 (0.02% betamethasone sodium phosphate in vehicle)Experimental Treatment1 Intervention
One drop twice daily (BID) in the study eye for 14 days.
Group III: VehiclePlacebo Group1 Intervention
One drop BID in the study eye for 14 days.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Ophthalmology Consultants Ltd.Saint Louis, MO
The Eye Associates of ManateeBradenton, FL
Coastal Research Associates, LLCRoswell, GA
Cincinnati Eye InstituteEdgewood, KY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Surface Pharmaceuticals, Inc.
Lead Sponsor
Trials
3
Patients Recruited
580+
Surface Ophthalmics, Inc.
Lead Sponsor
Trials
3
Patients Recruited
580+